Current Immunotherapy Treatments of Primary Breast Cancer Subtypes

Current Immunotherapy Treatments of Primary Breast Cancer Subtypes

Breast cancer receives the most funding when compared to any other cancer type, according to a global study conducted by <i>The Lancet</i>. Nevertheless, this malignancy remains the most diagnosed cancer among women and relies heavily on a neoadjuvant treatment regimen of chemotherapy an...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Savannah R. Brown, Emilie E. Vomhof-DeKrey
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	MDPI AG 2024-04-01
Σειρά:	Biomedicines
Θέματα:	breast cancer hormone receptor HER2 TNBC immunotherapy checkpoint inhibitors
Διαθέσιμο Online:	https://www.mdpi.com/2227-9059/12/4/895

Παρόμοια τεκμήρια

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
ανά: Ayoub NM, κ.ά.
Έκδοση: (2019-01-01)

Immunotherapy for HER-2 positive breast cancer
ανά: Tingting Yang, κ.ά.
Έκδοση: (2023-03-01)

MYC-Driven Pathways in Breast Cancer Subtypes
ανά: Yassi Fallah, κ.ά.
Έκδοση: (2017-07-01)

Immunotherapy for Triple-Negative Breast Cancer
ανά: Yifeng Cao, κ.ά.
Έκδοση: (2021-11-01)

A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
ανά: Tyler J. Nielsen, κ.ά.
Έκδοση: (2021-03-01)

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
ανά: Shi J, κ.ά.
Έκδοση: (2020-09-01)

Smoking history and breast cancer risk by pathological subtype: MCC-Spain study
ανά: Belén Peñalver-Argüeso, κ.ά.
Έκδοση: (2023-11-01)

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
ανά: Ruoning Yang, κ.ά.
Έκδοση: (2022-03-01)

Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment
ανά: Yalan Yang, κ.ά.
Έκδοση: (2024-10-01)

Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy
ανά: Andrea Nicolini, κ.ά.
Έκδοση: (2022-10-01)

Androgen Receptor Expression in ER and PR Negative Breast Cancer—A Study from a Tertiary Hospital in Northern India
ανά: Sumeet Sidhu, κ.ά.
Έκδοση: (2023-10-01)

Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
ανά: Filomena Marino Carvalho
Έκδοση: (2023-11-01)

Tumor microenvironment and immunotherapy for triple-negative breast cancer
ανά: Zijie Guo, κ.ά.
Έκδοση: (2024-12-01)

Classifying Breast Cancer Metastasis Based on Imaging of Tumor Primary and Tumor Biology
ανά: Barbara Awad, κ.ά.
Έκδοση: (2023-01-01)

Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment
ανά: Maria Vasileiou, κ.ά.
Έκδοση: (2023-05-01)

The neoepitope landscape of breast cancer: implications for immunotherapy
ανά: Pooja Narang, κ.ά.
Έκδοση: (2019-03-01)

Interaction between HER-2 and Hormone Receptors in Breast Cancer
ανά: Majid Moghadaszadeh, κ.ά.
Έκδοση: (2010-12-01)

Interaction between HER-2 and Hormone Receptors in Breast Cancer
ανά: Majid Moghadaszadeh, κ.ά.
Έκδοση: (2010-10-01)

Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment
ανά: Spyridon Giannopoulos, κ.ά.
Έκδοση: (2022-10-01)

Current and future immunotherapy for breast cancer
ανά: Natalie K. Heater, κ.ά.
Έκδοση: (2024-12-01)

Toll-like receptors in breast cancer immunity and immunotherapy
ανά: Joseph Zhou, κ.ά.
Έκδοση: (2024-06-01)

Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype
ανά: Jinqian Mao, κ.ά.
Έκδοση: (2021-04-01)

The evolving landscape of genetic biomarkers for immunotherapy in primary and metastatic breast cancer
ανά: Liang Jin, κ.ά.
Έκδοση: (2025-03-01)

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer
ανά: Ashley Schreier, κ.ά.
Έκδοση: (2023-01-01)

Liquid biopsy biomarkers to guide immunotherapy in breast cancer
ανά: Jinghan Yang, κ.ά.
Έκδοση: (2023-11-01)

Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
ανά: Mai F. Tolba, κ.ά.
Έκδοση: (2021-11-01)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
ανά: Hyungjoo Kim, κ.ά.
Έκδοση: (2022-05-01)

ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
ανά: J. A. Kyte, κ.ά.
Έκδοση: (2020-07-01)

Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
ανά: Anouchka Coste Holt, κ.ά.
Έκδοση: (2024-09-01)

Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention
ανά: Raj Pranap Arun, κ.ά.
Έκδοση: (2022-03-01)

Dual antibody-aided mesoporous nanoreactor for H2O2 self-supplying chemodynamic therapy and checkpoint blockade immunotherapy in triple-negative breast cancer
ανά: Ying-Tzu Chen, κ.ά.
Έκδοση: (2023-10-01)

Breast Cancer in Kirkuk City, Hormone Receptors Status (Estrogen and Progesterone) and Her-2/Neu and Their Correlation with Other Pathologic Prognostic Variables
ανά: Mahmoud Mohammed Mahmoud
Έκδοση: (2019-11-01)

Breast Cancer in Kirkuk City, Hormone Receptors Status (Estrogen and Progesterone) and Her-2/Neu and Their Correlation with Other Pathologic Prognostic Variables
ανά: Mahmoud Mohammed Mahmoud
Έκδοση: (2019-11-01)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
ανά: Xia Qiu, κ.ά.
Έκδοση: (2022-02-01)

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
ανά: Feng Ye, κ.ά.
Έκδοση: (2023-07-01)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
ανά: Can Chen, κ.ά.
Έκδοση: (2022-07-01)

Triple Negative Breast Cancer: A review of common therapeutic Targets and Current Treatment options.
ανά: Daud Akhtar, κ.ά.
Έκδοση: (2017-06-01)

The role of the sex hormone-gut microbiome axis in tumor immunotherapy
ανά: Luoyang Wang, κ.ά.
Έκδοση: (2023-12-01)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
ανά: Francesco Schettini, κ.ά.
Έκδοση: (2022-11-01)

Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients
ανά: Pooja M. Vaid, κ.ά.
Έκδοση: (2022-11-01)